Hematopoiesis News Volume 14.31 | Aug 08 2023

    By
    Noshin Noorjahan
    -
    0
    14








    2023-08-08 | HN 14.31


    Hematopoiesis News by STEMCELL Technologies
    Vol. 14.31 – 8 August, 2023
    TOP STORY

    Haplodeficiency of the 9p21 Tumor Suppressor Locus Causes Myeloid Disorders Driven by the Bone Marrow Microenvironment

    Researchers reported that mice with germ line monoallelic deletion or induced biallelic deletion of the 9p21-syntenic locus (9p21s) developed a fatal myelodysplastic syndrome/myeloproliferative neoplasm-like disease associated with aberrant trabecular bone formation and/or fibrosis in the bone marrow.
    [Blood]

    Abstract
    Image of erythroblasts which were simply & efficiently generated from PSCs using the STEMdiff Erythroid Kit.
    PUBLICATIONSRanked by the impact factor of the journal

    TET2-Mediated mRNA Demethylation Regulates Leukemia Stem Cell Homing and Self-Renewal

    Scientists showed that Tet2 deficiency significantly facilitated leukemogenesis in various AML models through promoting homing of leukemia stem cells into bone marrow niche to increase their self-renewal/proliferation.
    [Cell Stem Cell]

    AbstractGraphical Abstract

    Graft Conditioning with Fluticasone Propionate Reduces Graft-Versus-Host Disease Upon Allogeneic Hematopoietic Cell Transplantation in Mice

    The authors tested the hypothesis that donor cell conditioning with the glucocorticoid fluticasone propionate prior to transplantation could increase hematopoietic stem cell engraftment and reduce graft-versus-host disease.
    [EMBO Molecular Medicine]

    Full ArticleGraphical Abstract

    Kinase-Independent Role of mTOR and On-/Off-Target Effects of an mTOR Kinase Inhibitor

    Researchers employed an inducible kinase-inactive D2338A mTOR knock-in mouse model together with a mTOR conditional knockout model to assess the kinase-dependent/-independent function of mTOR in hematopoiesis and the on-/off-target effects of mTOR kinase inhibitor AZD2014.
    [Leukemia]

    Abstract

    Cohesin Subunit RAD21 Regulates the Differentiation and Self-Renewal of Hematopoietic Stem and Progenitor Cells

    To investigate the effects of perturbing the cohesin subunit protein RAD21 on normal hematopoiesis, investigators employed conditional knockout mouse models.
    [Stem Cells]

    AbstractGraphical Abstract

    Heterogeneity in Leukemia Cells That Escape Drug-Induced Senescence-Like State

    Using a single-cell assay to track individual cells that exited a drug-induced senescence-like state, scientists showed that cells exhibited asynchronous exit from a senescent-like state and displayed different rates of proliferation.
    [Cell Death & Disease]

    Full Article

    A Novel Subclonal Rearrangement of the STRN3::PDGFRB Gene in De Novo Acute Myeloid Leukemia with NPM1 Mutation and Its Leukemogenic Effects

    The authors reported a case of AML with a mutation in the NPM1 gene and a subclonal gene rearrangement involving the PDGFRB gene.
    [Cancer Gene Therapy]

    AbstractGraphical Abstract

    Genetic Events Associated with Venetoclax Resistance in CLL Identified by Whole-Exome Sequencing of Patient Samples

    Researchers analyzed longitudinal tumor samples from 11 patients with disease progression while receiving venetoclax to characterize the clonal evolution of resistance.
    [Blood]

    Abstract

    Rituximab Administration in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

    Children and adolescents with newly diagnosed B-acute lymphoblastic leukemia treated on the St. Jude Total XVII study were randomized to induction therapy with or without rituximab on day 3 or on days 6 and 24.
    [Leukemia]

    Abstract
    STEMCELL has implemented an Environmental Management System that is now ISO 14001-certified.
    REVIEWS

    Updates on Accelerated and Blast Phase Myeloproliferative Neoplasms: Are We Making Progress?

    Investigators provide an up-to-date summary of current understanding of the underlying pathogenesis of accelerated and blast phase myeloproliferative neoplasms and discuss current therapeutic approaches and realistic outcomes.
    [British Journal Of Haematology]

    Abstract
    INDUSTRY AND POLICY NEWS

    Ascentage Pharma Received Clearance from US FDA to Proceed with Global Registrational Phase III Clinical Trial for Lisaftoclax (APG-2575) in Previously Treated Patients with CLL/SLL

    Ascentage Pharma announced that lisaftoclax, a novel Bcl-2 inhibitor, has been cleared by the US FDA to enter a global registrational Phase III study for treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were previously treated with BTKi.
    [Ascentage Pharma]

    Press Release
    FEATURED EVENT

    AFLAS Congress 2023

    September 13 – 15, 2023
    Seogwipo, South Korea

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Scientist – Cancer Research Cluster

    Cedars-Sinai – Los Angeles, California, United States

    Postdoctoral Project Research Scientist – Signaling and Structural Laboratory

    Francis Crick Institute – London, England, United Kingdom

    Postdoctoral Position – Proteostasis, Hematopoiesis, and AML

    National Institutes of Health – Bethesda, Maryland, United States

    Scientific Director – Clinical Research

    NCI Center for Cancer Research – Bethesda, Maryland, United States

    Associate Professor – Pediatric Blood and Marrow Transplantation

    Fred Hutchinson Cancer Center – Seattle, Washington, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter